Ocugen, Inc. Common Stock
$1.06
$0.03 (+2.91%)
$1.00Day Range$1.08
Key Statistics
Market Cap
$359.46M
Shares Outstanding
339.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 3, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$1.02
Day High
$1.08
Day Low
$1.00
Volume
14.76M
VWAP
$1.05
Prev Close
$1.03
Transactions
--
Acc. Volume
--
About Ocugen, Inc. Common Stock
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836116 employees11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355484-328-4701IPO Dec 3, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001372299
- Composite FIGI
- BBG00194VJB1
- Share Class FIGI
- BBG001TG1LS2
- Ticker Root
- OCGN
- SIC Code
- 2836
About Ocugen, Inc. Common Stock (OCGN) Stock
Ocugen, Inc. Common Stock (OCGN) closed the 2026-09-18 session at $1.06, up 2.91% versus the previous close (+0.03). The stock opened at $1.02 and traded between $1.00 and $1.08 during that session. Session trading volume was 14.8M shares. The volume-weighted average price (VWAP) is $1.05.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ocugen, Inc. Common Stock has a market capitalization of $359.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. OCGN is listed on the XNAS exchange. The company employs approximately 116 people. Ocugen, Inc. Common Stock is headquartered in MALVERN, PA. The recorded listing date is 2014-12-03.
On this page you can find market OCGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.